George Mias

Dr. George Mias


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Cell
Verified
Journal Article
Closed access
RCRui Chen
Rui Chen
GMGeorge Mias
George Mias
JLJennifer Li-Pook-Than
Jennifer Li-Pook-Than
LJLihua Jiang
Lihua Jiang
HLHugo Y.K. Lam
Hugo Y.K. Lam
MSMichael P Snyder
Michael P Snyder

22 June 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LBLavida R. K. Brooks
Lavida R. K. Brooks
GMGeorge Mias
George Mias
Streptococcus pneumoniae is an infectious pathogen responsible for millions of deaths worldwide. Diseases caused by this bacterium are classified as pneumococcal diseases. This pathogen colonizes the nasopharynx of its host asymptomatically, but overtime can migrate to sterile tissues and organs and cause infections. Pneumonia is currently the most common pneumococcal disease. Pneumococcal pneumonia is a global health concern and vastly affects children under the age of five as well as the elderly and individuals with pre-existing health conditions. S. pneumoniae has a large selection of virulence factors that promote adherence, invasion of host tissues, and allows it to escape host immune defenses. A clear understanding of S. pneumoniae’s virulence factors, host immune responses, and examining the current techniques available for diagnosis, treatment, and disease prevention will allow for better regulation of the pathogen and its diseases. In terms of disease prevention, other considerations must include the effects of age on responses to vaccines and vaccine efficacy. Ongoing work aims to improve on current vaccination paradigms by including the use of serotype-independent vaccines, such as protein and whole cell vaccines. Extending our knowledge of the biology of, and associated host immune response to S. pneumoniae is paramount for our improvement of pneumococcal disease diagnosis, treatment, and improvement of patient outlook.

17 July 2020 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
EVEren M. Veziroglu
Eren M. Veziroglu
GMGeorge Mias
George Mias
Cells release nanometer-scale, lipid bilayer-enclosed biomolecular packages (extracellular vesicles; EVs) into their surrounding environment. EVs are hypothesized to be intercellular communication agents that regulate physiological states by transporting biomolecules between near and distant cells. The research community has consistently advocated for the importance of RNA contents in EVs by demonstrating that: (1) EV-related RNA contents can be detected in a liquid biopsy, (2) disease states significantly alter EV-related RNA contents, and (3) sensitive and specific liquid biopsies can be implemented in precision medicine settings by measuring EV-derived RNA contents. Furthermore, EVs have medical potential beyond diagnostics. Both natural and engineered EVs are being investigated for therapeutic applications such as regenerative medicine and as drug delivery agents. This review focuses specifically on EV characterization, analysis of their RNA content, and their functional implications. The NIH extracellular RNA communication (ERC) program has catapulted human EV research from an RNA profiling standpoint by standardizing the pipeline for working with EV transcriptomics data, and creating a centralized database for the scientific community. There are currently thousands of RNA-sequencing profiles hosted on the Extracellular RNA Atlas alone (Murillo et al., 2019), encompassing a variety of human biofluid types and health conditions. While a number of significant discoveries have been made through these studies individually, integrative analyses of these data have thus far been limited. A primary focus of the ERC program over the next five years is to bring higher resolution tools to the EV research community so that investigators can isolate and analyze EV sub-populations, and ultimately single EVs sourced from discrete cell types, tissues, and complex biofluids. Higher resolution techniques will be essential for evaluating the roles of circulating EVs at a level which impacts clinical decision making. We expect that advances in microfluidic technologies will drive near-term innovation and discoveries about the diverse RNA contents of EVs. Long-term translation of EV-based RNA profiling into a mainstay medical diagnostic tool will depend upon identifying robust patterns of circulating genetic material that correlate with a change in health status.

1 September 2013 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
RCRui Chen
Rui Chen
SGSilvia Giliani
Silvia Giliani
GLGaetana Lanzi
Gaetana Lanzi
GMGeorge Mias
George Mias
SLSilvia Lonardi
Silvia Lonardi
LNLuigi Daniele Notarangelo
Luigi Daniele Notarangelo

23 March 2023 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
RSRyan T. Scott
Ryan T. Scott
LSLauren M. Sanders
Lauren M. Sanders
EAErik L. Antonsen
Erik L. Antonsen
JHJaden J. A. Hastings
Jaden J. A. Hastings
SPSeung-min Park
Seung-min Park
Sylvain CostesSylvain Costes
Sylvain Costes

3 September 2013 in Metabolites
Verified
Journal Article
Open access
PDF file
LSLarissa Stanberry
Larissa Stanberry
GMGeorge Mias
George Mias
MSMichael P Snyder
Michael P Snyder
MSMichael P Snyder
Michael P Snyder
MSMichael Snyder
Michael Snyder
MSMichael P Snyder
Michael P Snyder
The integrative personal omics profile (iPOP) is a pioneering study that combines genomics, transcriptomics, proteomics, metabolomics and autoantibody profiles from a single individual over a 14-month period. The observation period includes two episodes of viral infection: a human rhinovirus and a respiratory syncytial virus. The profile studies give an informative snapshot into the biological functioning of an organism. We hypothesize that pathway expression levels are associated with disease status. To test this hypothesis, we use biological pathways to integrate metabolomics and proteomics iPOP data. The approach computes the pathways’ differential expression levels at each time point, while taking into account the pathway structure and the longitudinal design. The resulting pathway levels show strong association with the disease status. Further, we identify temporal patterns in metabolite expression levels. The changes in metabolite expression levels also appear to be consistent with the disease status. The results of the integrative analysis suggest that changes in biological pathways may be used to predict and monitor the disease. The iPOP experimental design, data acquisition and analysis issues are discussed within the broader context of personal profiling.